Clinical Trials Logo

Metastatic Soft Tissue Sarcoma clinical trials

View clinical trials related to Metastatic Soft Tissue Sarcoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05100628 Terminated - Clinical trials for Metastatic Soft-tissue Sarcoma

A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

Start date: February 11, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination of NOX66 and doxorubicin.

NCT ID: NCT03670069 Terminated - Clinical trials for Metastatic Soft Tissue Sarcoma

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Start date: September 30, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.